Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 25 of 571 for:    Genetic AND SNP

Genetic Variants in Egyptian Patients Receiving HCQ(Hydroxychloroquine) (HCQ)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03180190
Recruitment Status : Unknown
Verified June 2017 by nesreen ismail ibrahim, Assiut University.
Recruitment status was:  Not yet recruiting
First Posted : June 8, 2017
Last Update Posted : June 9, 2017
Sponsor:
Information provided by (Responsible Party):
nesreen ismail ibrahim, Assiut University

Brief Summary:

Hydroxychloroquine(HCQ)play major role in management of many rheumatic diseases.

Retinal toxicity from HCQ is serious side effect because even after the drug drug is discontinued, there is little if any visual recovery. For this reason, regular screening for retinal toxicity is recommended to detect early retinopathy and discontinue the therapy.

Cytochrome P450 (CYP) enzymes play major roles in drug metabolism. Certain single-nucleotide polymorphisms(SNPs) in CYP genes may have a large impact on CYP enzyme activity.Polymorphisms in the cytochrome P450 gene might influence blood concentration some patients have a genetic predisposition to HCQ toxicity (e.g.,from abnormalities in the ABCA4 gene)Which is not studied previously among Egyptian population


Condition or disease Intervention/treatment
Autoimmune Diseases Drug: Hydroxychloroquine Oral Tablet

Detailed Description:

The antimalarial agent hydroxychloroquine have been used widely for the treatment of rheumatoid arthritis and systemic lupus erythematosus.

Among rheumatic diseases, the primary role of HCQ is in the management of articular and skin manifestations of systemic lupus erythematosus (SLE) and the treatment of mild to moderately active rheumatoid arthritis (RA). As a cornerstone of SLE management, HCQ leads to reduction in the risk of disease flare as well as providing a valuable adjunct in the therapy of lupus nephritis, and is a relatively safe option for t0reatment of SLE during pregnancy,It also has been linked to the prevention thrombosis as well as a reduced risk of permanent organ damage. HCQ's beneficial effects on lipid levels and reduction in the risk of diabetes .It is a member of the "triple therapy" triad for the treatment of RA , serving as an important component of the therapeutic approach in active disease. Other less common uses for HCQ include the treatment of palindromic rheumatism, Inflammatory cutaneous disorders, and the antiphospholipid antibody syndrome because of its antithrombotic effect .

Retinal toxicity from HCQ is of serious ophthalmologic concern. Because even after the drug is discontinued, there is little if any visual recovery. Additionally, it has been shown that the retinal degeneration caused by HCQ can continue to progress. For this reason, regular screening for retinal toxicity is recommended to detect early retinopathy and discontinue the therapy.

The exact mechanism of HCQ and CQ toxicity remains unclear. Previously, it was hypothesized that retinal toxicity results from binding of HCQ and CQ to melanin in the retinal pigment epithelium (RPE), thus damaging the overlying photoreceptors and ultimately causing vision loss .Whether the primary effect of antimalarials occurs at the level of the RPE versus the retinal photoreceptors has been debated, however, as newer imaging technology has become available ,Early retinal toxicity is generally asymptomatic, with subtle alterations in foveal pigmentation that are often not evident on routine ophthalmologic examination. As toxicity progresses, classic "bull's eye" maculopathy, representing a ring of parafoveal RPE depigmentation sparing the central fovea, may be noted. Progression leads to increasing visual impairment, symptomatically manifesting as decreased central vision, reduced color vision, reduced night vision, reading difficulties, central scotomata, flashing lights, and increasing visual field defects.

Cytochrome P450 (CYP) enzymes play major roles in drug metabolism. Certain single-nucleotide polymorphisms(SNPs) in CYP genes may have a large impact on CYP enzyme activity.Polymorphisms in the cytochrome P450 gene might influence blood concentration.

HCQ is metabolized to N-desethyl HCQ (DHCQ) in the liver through the N-desethylation pathway,This reaction is mediated by CYP 2D6, 3A4, 3A5, and 2C8 isoforms.

some patients have a genetic predisposition to HCQ toxicity (e.g.,from abnormalities in the ABCA4 gene) However, in 2015 ABCA4 polymorphisms proposed that could be protective agent. Which is not studied previously among Egyptian population


Layout table for study information
Study Type : Observational [Patient Registry]
Estimated Enrollment : 50 participants
Observational Model: Case-Only
Time Perspective: Cross-Sectional
Target Follow-Up Duration: 1 Year
Official Title: Cytochrome P450 and ATP-Binding Cassette C C (ABCC) Variants in Egyptian Patients Receiving Hydroxychloroquine and Their Association With Efficacy and Toxicity
Estimated Study Start Date : June 28, 2017
Estimated Primary Completion Date : June 28, 2018
Estimated Study Completion Date : July 28, 2018

Resource links provided by the National Library of Medicine


Group/Cohort Intervention/treatment
patients with ocular toxicity

Screening for ophthalmic exclusion criteria by slit lamp and fundus examination using both direct and indirect ophthalmoscope Screening for HCQ ocular toxicity by

  • Perimetry using Octopus perimeter and utilizing 24-2 test strategy,
  • Electroretinography (ERG) under scotopic and photopic conditions and Spectral domain optical coherence tomography (SD-OCT) genotyping using real time PCR (Taqman discrimination assay) for study frequency of single nucleotide polymorphisms (SNPs) of CYP2C19, CYP1A2, and ABCG2.
Drug: Hydroxychloroquine Oral Tablet

slit lamp and fundus examination using both direct and indirect ophthalmoscope Screening for HCQ ocular toxicity by

  • Perimetry using Octopus perimeter and utilizing 24-2 test strategy,
  • Electroretinography (ERG) under scotopic and photopic conditions and Spectral domain optical coherence tomography (SD-OCT)
Other Name: diagnostic test

patients without ocular toxicity

Screening for ophthalmic exclusion criteria by slit lamp and fundus examination using both direct and indirect ophthalmoscope Screening for HCQ ocular toxicity by

  • Perimetry using Octopus perimeter and utilizing 24-2 test strategy,
  • Electroretinography (ERG) under scotopic and photopic conditions and Spectral domain optical coherence tomography (SD-OCT) genotyping using real time PCR (Taqman discrimination assay) for study frequency of single nucleotide polymorphisms (SNPs) of CYP2C19, CYP1A2, and ABCG2.
Drug: Hydroxychloroquine Oral Tablet

slit lamp and fundus examination using both direct and indirect ophthalmoscope Screening for HCQ ocular toxicity by

  • Perimetry using Octopus perimeter and utilizing 24-2 test strategy,
  • Electroretinography (ERG) under scotopic and photopic conditions and Spectral domain optical coherence tomography (SD-OCT)
Other Name: diagnostic test




Primary Outcome Measures :
  1. HCQ toxicity in Egyptian patients [ Time Frame: 1 year ]
    Recognizing clinical and genetic factor(s) affecting the outcome of HCQ therapy in Egyptian patients population and /or predisposing to its toxicity.


Secondary Outcome Measures :
  1. genetic variant [ Time Frame: 1 year ]
    Detecting the frequency (distribution) of single nucleotide polymorphisms (SNPs) of CYP and ABCC in Egyptian patients


Biospecimen Retention:   Samples Without DNA
5 ml of blood will be collected into tubes containing EDTA, and stored immediately at −80 for genomic DNA extraction and genotyping using real time PCR (Taqman discrimination assay) for study frequency of single nucleotide polymorphisms (SNPs)of CYP2C19, CYP1A2, and ABCG2.


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 60 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Probability Sample
Study Population
All patients receiving HCQ treatment
Criteria

Inclusion Criteria:

  • All patients received HCQ treatment and attending the Rheumatology and Rehabilitation outpatient clinic and in-patient department, Faculty of Medicine, Assiut University Hospitals.

Exclusion Criteria:

  • • Patients less than 18 years old.

    • Patients with co-morbidities (e.g., liver disease, serious infections, or cardiac, respiratory, gastrointestinal, endocrine disease) that could influence the disease activity and the liver condition.
    • Patients with Renal failure (creatinine clearance < 30 ml/ min).
    • Patients with ophthalmic conditions that may give rise to abnormalities in the screening tests used to detect HCQ toxicity e.g. glaucoma, hereditary fundus dystrophies, dense media opacity precluding fundus visibility, optic neuritis and uveitis.
    • Patients receiving tamoxifen or other retinal toxin drugs.

Additional Information:

Layout table for additonal information
Responsible Party: nesreen ismail ibrahim, principle investigator, Assiut University
ClinicalTrials.gov Identifier: NCT03180190     History of Changes
Other Study ID Numbers: Hydroxychloroquine
First Posted: June 8, 2017    Key Record Dates
Last Update Posted: June 9, 2017
Last Verified: June 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Layout table for MeSH terms
Autoimmune Diseases
Immune System Diseases
Hydroxychloroquine
Antimalarials
Antiprotozoal Agents
Antiparasitic Agents
Anti-Infective Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Antirheumatic Agents